Demographic and clinical parameters of the cohort
| CR (n=5) | PR (n=10) | NR (n=4) | p Value (CR vs NR) | p Value (CR vs PR | p Value (PR vs NR) | |
|---|---|---|---|---|---|---|
| Age (years) | 24.8±4.97 | 34±5.35 | 30±8.16 | NS | 0.035* | NS |
| Female (%) | 4 (80) | 8 (80) | 4 (100) | NS | NS | NS |
| Class IV (%) | 3 (60) | 9 (90) | 4 (100) | NS | NS | NS |
| No treatment prior to biopsy (%)† | 0% | 40% | 25% | NS | NS | NS |
| Cyclophosphamide induction (%) | 2 (40) | 3 (30) | 2 (50) | NS | NS | NS |
| MMF induction (%) | 3 (60) | 7 (70) | 2 (50) | NS | NS | NS |
| SCr‡ at diagnosis | 0.94±0.31 | 1.08±0.53 | 1.08±0.28 | NS | NS | NS |
| SCr after induction | 0.74±0.15 | 0.81±0.12 | 1.18±0.36 | 0.0129 | NS | 0.018 |
| Proteinuria§ at diagnosis | 3.04±1.11 | 4.38±1.09 | 5.5±2.08 | 0.043 | NS | NS |
| Proteinuria after induction | 0.24±0.09 | 1.49±0.51 | 3.33±1.27 | <0.0001 | 0.0114 | 0.0009 |
| First flare (%) | 3 (60%) | 8 (80%) | 1 (25%) | NS | NS | NS |
| Median activity index (range) | 6 (4–8) | 8 (4–12) | 5 (4–12) | NS | NS | NS |
| Median chronicity index (range) | 2 (0–4) | 4 (2–5) | 5 (0–6) | NS | NS | NS |
*For clinical variables t test, analysis of variance or Wilcoxon rank-sum tests were done, followed by Bonferroni post hoc testing for multiple comparisons as appropriate.
†Patients on treatment for systemic lupus erythematosus were on either azathioprine and/or prednisone (see text).
‡Serum creatinine concentration in mg/dL.
§Urine protein in g/day.
CR, complete renal response group; MMF, mycophenolate mofitel; NS, not significant; NR, non-responder group; PR, partial renal response group.